Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Biotechnology

Healthcare
$7.21 +6.61%

+$0.46 today

Market cap
$89.11M
Beta
1.05
P/E (TTM)
-11.1
EPS (TTM)
-$0.67
52W Low $0.68High $7.78

Volume 0.61M

Average 0.12M

LIXT Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 134.8% from a year ago

Cash & equivalents stood at $3.25M at the end of Q1 FY2026, up 134.8% from a year earlier and down 36.3% from the prior quarter. Over 3 fiscal years it compounded at -1.6% a year.

Context

  • Cash & equivalents amounted to 29.9% of total assets at the end of Q1 FY2026, down 61.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +134.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.25M-36.3% QoQ
Last fiscal yearDec 2025
$5.11M+391.5% YoY
Year agoMar 2025
$1.38M+134.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+134.8%——
1 year+391.5%——
3-year CAGR-1.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
5.11M USD
Year-over-year change
+391.5%
4-year CAGR
+1.4%

Cash & Equivalents vs competitors

How LIXT compares with its peers on the latest reported figures

  • LIXT's Mar 2026 cash & equivalents of $3.25M is the lowest of the 2 companies compared; the peer median is $25.89M.
  • Its year-over-year change of +134.8% is the lowest of 2, against a peer median of +172.0%.
  • Cash & equivalents amounts to 29.9% of total assets for LIXT, versus a peer median of 83.9%.
LIXT Competitors Peer median
Cash & Equivalents for LIXT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CINGCingulate Inc.Mar 2026$25.89M +172.0%+26.9%83.9%
LIXTLixte Biotechnology Holdings, Inc.Mar 2026$3.25M +134.8%-1.6%29.9%
Peer median (excluding LIXT) $25.89M+172.0%+26.9%83.9%

Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.82M5.35M4.2M1.04M5.11M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets150.24K00(106.55K)0
Total Current Assets5.09M5.56M4.31M1.04M5.18M
Property, Plant & Equipment (Net)00007.56M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets000106.55K0
Total Non-current Assets000106.55K7.56M
Total Assets5.09M5.56M4.31M1.15M12.73M
Account Payables193.47K183.75K120.51K83.21K436.48M
Short-term Debt000069.07K
Tax Payables00000
Deferred Revenue0165.02K157.1K235.08K232.14K
Other Current Liabilities76.96K000(436.05M)
Total Current Liabilities302.93K395.76K313.86K318.28K1.33M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities(0)000438.96K
Total Non-current Liabilities(0)000438.96K
Total Liabilities302.93K395.76K313.86K318.28K1.77M
Common Stock1.37K166225225879
Retained Earnings(37.08M)(43.39M)(48.48M)(52.07M)(58.08M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00001.3M
Total Equity4.79M5.17M3.99M827.22K10.96M
Total Debt0000664.49K
Net Debt(4.82M)(5.35M)(4.2M)(1.04M)(4.44M)

Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Intrinsic Alpha fair value

Locked

Current Price

$7.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.